Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Mobia Medical is an emerging commercial-stage medical technology company that develops the Vivistim system, a vagus nerve stimulation device designed to restore upper extremity motor function in ischemic stroke survivors. Minot Light is aggressively bullish, exploiting technical selling pressure following its May 2026 initial public offering that depressed the market cap below institutional ownership thresholds. From an economic perspective, Vivistim possesses an immense regulatory and commercial moat as the sole FDA-approved therapy addressing a multi-billion dollar unmet clinical market across both acute and chronic stroke patient populations. The product exhibits superior software-like unit economics with gross margins exceeding 80%. As commercial infrastructure scales across specialized stroke centers, the company is poised to unlock substantial operating leverage, with targeted normalized EBITDA margins reaching 25%. The enterprise is currently valued at roughly 2x EV/Sales and $8.30 per share, with $170 million in net cash ($5.00 per share) representing over 60% of its market capitalization and providing an exceptional margin of safety compared to standard early-stage MedTech multiples of 6x to 8x revenue. Key catalysts include rapid adoption via hospital referral channels, inclusion in American Heart Association clinical guidelines, and projected top-line growth exceeding 50% toward $75 million in 2027. Primary risks involve the complexity of establishing coordinated hospital-therapist referral networks, near-term cash burn, and commercial execution bottlenecks.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.